S&P 500

5.473,23

0,00%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Pluristem Therapeutics Inc (PSTI)
Pluristem Therapeutics Inc (PSTI) Notícias

PSTI

Pluristem Therapeutics (PSTI)

Pluristem Therapeutics Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:PSTI

1 2 3 4 5 6 7 8 9 10 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
09/06/2023	07:04	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:PSTI	Pluristem Therapeutics Inc
01/06/2023	17:06	Edgar (US Regulatory)	Securities Registration Statement (simplified Form) (s-3)	NASDAQ:PSTI	Pluristem Therapeutics Inc
09/05/2023	17:17	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:PSTI	Pluristem Therapeutics Inc
25/04/2023	17:02	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:PSTI	Pluristem Therapeutics Inc
27/02/2023	09:58	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NASDAQ:PSTI	Pluristem Therapeutics Inc
27/02/2023	09:53	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:PSTI	Pluristem Therapeutics Inc
16/02/2023	10:59	Edgar (US Regulatory)	Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)	NASDAQ:PSTI	Pluristem Therapeutics Inc
16/02/2023	10:17	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:PSTI	Pluristem Therapeutics Inc
14/02/2023	08:27	Edgar (US Regulatory)	Amended Current Report Filing (8-k/a)	NASDAQ:PSTI	Pluristem Therapeutics Inc
13/02/2023	18:39	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:PSTI	Pluristem Therapeutics Inc
22/12/2022	10:55	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:PSTI	Pluristem Therapeutics Inc
21/09/2022	18:17	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:PSTI	Pluristem Therapeutics Inc
21/09/2022	17:03	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:PSTI	Pluristem Therapeutics Inc
25/07/2022	08:00	GlobeNewswire Inc.	Pluri CEO Issues Shareholder Update	NASDAQ:PSTI	Pluristem Therapeutics Inc
25/07/2022	02:00	GlobeNewswire Inc.	Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries	NASDAQ:PSTI	Pluristem Therapeutics Inc
17/07/2022	09:20	TipRanks	Pluristem (PSTI) Receives a Buy from H.C. Wainwright	NASDAQ:PSTI	Pluristem Therapeutics Inc
13/07/2022	07:00	GlobeNewswire Inc.	Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery	NASDAQ:PSTI	Pluristem Therapeutics Inc
15/05/2022	09:25	TipRanks	Dawson James Thinks Pluristem’s Stock is Going to Recover	NASDAQ:PSTI	Pluristem Therapeutics Inc
28/03/2022	04:00	GlobeNewswire Inc.	Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership	NASDAQ:PSTI	Pluristem Therapeutics Inc
23/03/2022	08:30	GlobeNewswire Inc.	Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions	NASDAQ:PSTI	Pluristem Therapeutics Inc
08/03/2022	09:12	GlobeNewswire Inc.	Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture	NASDAQ:PSTI	Pluristem Therapeutics Inc
02/03/2022	09:00	GlobeNewswire Inc.	Pluristem CEO Issues Shareholder Update	NASDAQ:PSTI	Pluristem Therapeutics Inc
24/02/2022	09:00	GlobeNewswire Inc.	Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform	NASDAQ:PSTI	Pluristem Therapeutics Inc
10/01/2022	05:00	GlobeNewswire Inc.	Biotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform	NASDAQ:PSTI	Pluristem Therapeutics Inc
05/01/2022	06:11	TipRanks	Dawson James Maintains a Buy Rating on Pluristem (PSTI)	NASDAQ:PSTI	Pluristem Therapeutics Inc
27/12/2021	09:00	GlobeNewswire Inc.	Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19	NASDAQ:PSTI	Pluristem Therapeutics Inc
15/11/2021	09:10	GlobeNewswire Inc.	Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery	NASDAQ:PSTI	Pluristem Therapeutics Inc
10/11/2021	09:00	GlobeNewswire Inc.	Pluristem Receives Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX Platform	NASDAQ:PSTI	Pluristem Therapeutics Inc
26/07/2021	17:20	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:PSTI	Pluristem Therapeutics Inc
19/07/2021	08:00	GlobeNewswire Inc.	Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors	NASDAQ:PSTI	Pluristem Therapeutics Inc